Ministry seeks tighter norms for antimicrobials, bulk trade
FlashcardsQuick reviseKey facts. One by one.Start →In this note
- At a Glance
- Why in the News
- Background & Evolution
- Core Static Facts
- Multi-Dimensional Analysis
- Recent Developments (last 12–18 months)
- Prelims Hooks
- How States Could License Antibiotics the Centre Never Approved
- Why Earlier Bans Did Not Clear the Shelves
- The Case Against Centralising, and What It Gets Right
- What the Bulk-Drug Licence Leaves Out: Factory Waste
- Anchors for Answers
- Mains Relevance
- Related Topics to Study Next
- NCERT Concepts to Revise
- Common Errors / Trap Areas
1. At a Glance
- The Union Health Ministry has proposed amending the New Drugs and Clinical Trials (NDCT) Rules, 2019 so that 'antimicrobials' fall within the definition of 'New Drug' [1].
- The aim is to stop manufacturing licences for antimicrobial products being granted without adequate regulatory scrutiny, given that antimicrobial resistance (AMR) is a major global public-health concern [1].
- A second proposal amends the Drugs Rules, 1945 to create a separate application form and licence form for the sale of bulk drugs, distinct from the licensing provisions for formulations [1].
- Why it matters for UPSC: it links GS-II (health governance, regulation), GS-III (pharma sector, biotechnology) and the One Health approach behind India's NAP-AMR 2.0 [1][2].
2. Why in the News
- 20 November 2026: The Hindu (Page 6, International edition) reported the Ministry's draft amendments to the NDCT Rules, 2019 and the Drugs Rules, 1945 [1].
- Context: India released the second version of its National Action Plan on AMR (NAP-AMR 2.0) during World AMR Awareness Week (WAAW) 2025 [2].
3. Background & Evolution
- Rationale: AMR is a recognised global public-health threat. The worry is that antimicrobial products are being licensed without enough regulatory scrutiny [1].
- Milestones:
- 1940: Drugs and Cosmetics Act enacted. It is the parent statute for drug rules [verify].
- 1945: Drugs Rules framed. The current proposal amends them for bulk-drug sale licensing [1].
- 2017–2021: India's first NAP-AMR. WHO India describes it as a technical document that summarises the status of AMR containment in India, together with the action plan [3].
- 2019: NDCT Rules, 2019 notified. They are the rules now proposed for amendment [1].
- 2025 (WAAW): NAP-AMR 2.0 released [2].
-
Nov 2026: Draft amendments add antimicrobials to the 'New Drug' definition and create a separate bulk-drug sale licence [1].
-
Related earlier steps: Schedule H1 (2013) restricts over-the-counter sale of certain antibiotics; the Chennai Declaration (2012); the "Red Line" campaign on antibiotic packs (2016) [verify].
4. Core Static Facts
| Item | Fact |
|---|---|
| Proposing body | Union Ministry of Health & Family Welfare [1] |
| Rules amended (1) | New Drugs and Clinical Trials Rules, 2019: 'antimicrobials' added to the 'New Drug' definition [1] |
| Rules amended (2) | Drugs Rules, 1945: separate application form + licence form for sale of bulk drugs [1] |
| Bulk drug vs formulation | The new bulk-drug licence will be distinct from the existing licensing for formulations [1] |
| Parent Act | Drugs and Cosmetics Act, 1940 [verify] |
| National regulator | CDSCO, headed by the Drugs Controller General of India (DCGI), under MoHFW [verify] |
| Statutory advisory bodies | DTAB (technical) and DCC (State–Centre consultative) under the D&C Act [verify] |
| Policy framework | NAP-AMR 2.0, released at WAAW 2025 [2]; predecessor NAP-AMR 2017–2021 [3] |
| Approach | One Health: human, animal, agriculture, food and environment sectors [verify] |
- Key terms:
- Antimicrobials: antibiotics, antivirals, antifungals and antiparasitics [verify].
- AMR: microbes that no longer respond to the drugs used against them.
- Bulk drug / API: the active ingredient.
- Formulation: the finished dosage form.
5. Multi-Dimensional Analysis
Legal / Regulatory
- Classing antimicrobials as "new drugs" brings every such product under the NDCT approval route, which tightens scrutiny before manufacturing licences are granted [1].
- Antimicrobials would likely move from state-level generic licensing to central approval. This is a federal shift in drug regulation [verify].
- A separate bulk-drug sale licence closes a gap where API trade was handled within the formulation licensing provisions [1].
Public Health
- The proposal targets AMR, which is a major global public-health concern [1].
- It supports NAP-AMR 2.0 objectives on rational antimicrobial use [2].
Economic / Industrial
- India's generic-antibiotic industry would face higher compliance costs and possibly slower launches of new combinations [verify].
- Bulk-drug licensing brings traceability to API trade. This matters for supply-chain integrity alongside the PLI scheme for APIs [verify].
Governance / Administrative
- The central regulator's workload would grow, so CDSCO capacity and Centre–State coordination become critical [verify].
- The proposal targets licences granted without adequate scrutiny, which points to weak oversight [1].
Environmental (One Health)
- AMR spreads through pharma effluents, hospital waste and farm use. A national plan covering many sectors addresses this [2].
6. Recent Developments (last 12–18 months)
- WAAW 2025 (November 2025): India releases the second National Action Plan on AMR (NAP-AMR 2.0) [2].
- 20 Nov 2026: The Health Ministry proposes adding antimicrobials to the 'New Drug' definition under the NDCT Rules, 2019 [1].
- 20 Nov 2026: The Ministry proposes a separate bulk-drug sale application form and licence form under the Drugs Rules, 1945 [1].
7. Prelims Hooks
- The proposal amends the New Drugs and Clinical Trials Rules, 2019 to include 'antimicrobials' in the 'New Drug' definition [1].
- Proposing ministry: Union Ministry of Health & Family Welfare, not the Department of Pharmaceuticals [1].
- The bulk-drug sale licensing change is made under the Drugs Rules, 1945 [1].
- The bulk-drug licence will be distinct from the licensing for formulations [1].
- India's first NAP-AMR covered 2017–2021 [3].
- NAP-AMR 2.0 was released during World AMR Awareness Week 2025 [2].
- WHO India describes NAP-AMR (2017–21) as a technical document summarising AMR containment status [3].
- WAAW is observed annually from 18–24 November [verify].
- Schedule H1 of the Drugs Rules covers certain antibiotics and needs a prescription register [verify].
- CDSCO is headed by the DCGI [verify].
8. How States Could License Antibiotics the Centre Never Approved
- Two regulators, one gap between them
- The Centre decides whether a new drug is safe and works. State drug authorities give the licences to make and sell drugs [6].
- In 2012, the Parliamentary Standing Committee on Health looked at how CDSCO works. It covered the approval of new drugs and the banning of drugs [6].
-
A study of antibiotic use in India in 2019 named this overlap of central and State powers as one reason why so many antibiotics are used [4].
-
Why putting antimicrobials in the 'New Drug' definition matters
- Once every antimicrobial counts as a 'New Drug', the Centre must approve it before anyone can get a manufacturing licence [1].
-
This goes straight at what the Ministry is worried about: licences given without proper checks [1].
-
The scale of the problem
- The same study found that over half of the antibiotic formulations (finished medicines) used in India in 2019 were unapproved [4].
- It also blamed the large number of FDCs (fixed-dose combinations, two or more drugs mixed in one pill) being made and sold [4].
9. Why Earlier Bans Did Not Clear the Shelves
- A rule on paper is not a drug off the market
- The government banned some unapproved FDCs, including antibiotic ones, most recently in 2016 [5].
- Industry challenged the bans in court, and the FDCs seem to have stayed on sale [5].
-
So the new rule will be tested in the same way. Will the Centre enforce it against products that are already sold, or only against new applications?
-
Licensing controls the factory, not the chemist's counter
- The 2019 study found most antibiotics could be bought over the counter (without a prescription) with no restriction. It called this a main reason for high use [4].
- 'Watch' antibiotics made up 54.9% of all use, measured in DDDs (defined daily doses, a standard unit for counting how much of a drug is used) [4].
- 'Watch' is a WHO group of antibiotics that carry a higher risk of resistance and should be used with care.
- Stricter licences cannot change what a chemist sells. That needs enforcement at the retail level, and the proposal [1] does not cover it.
10. The Case Against Centralising, and What It Gets Right
- The strongest objection: the Centre is stretched too
- Moving every antimicrobial to central approval means CDSCO gets many more files. Approvals could slow down, and so could launches of cheap generics.
- Parliament's own committees have said the drug-control system is weak at both levels. The 2013 Standing Committee report pointed to weak drug-control set-ups in the States and at the Centre [7].
-
This point is fair. A file moved to a busy office is not a file checked properly.
-
Why the shift still makes sense
- The same 2013 committee recommended that the licensing of drug manufacture be centralised, because of these weaknesses [7].
-
Checking at one central point is easier to make consistent than 36 different State standards. This matters most for antimicrobials, where one bad approval adds to resistance everywhere [1].
-
What should go with it
- MoHFW should add staff and deadlines to the rule. Centralising without more CDSCO capacity just moves the delay. The 2013 committee's push to centralise came with a call to fix weak drug-control infrastructure [7].
11. What the Bulk-Drug Licence Leaves Out: Factory Waste
- Antibiotic pollution from factories is mostly unregulated
- WHO says antibiotic pollution from manufacturing is largely unregulated. Normal quality checks usually ignore what a factory releases into the environment [8].
-
Antibiotic traces in factory wastewater can breed resistant microbes in rivers and soil. This is the One Health link (human, animal and environmental health are connected).
-
The new licence tracks who sells APIs, not what the plant releases
- The draft creates a separate form and licence for selling bulk drugs [1]. It says nothing about discharge from API plants.
-
WHO's 2024 guidance covers every stage, from making APIs (active pharmaceutical ingredients) to the finished medicine and its packaging [8].
-
What could follow
- CDSCO and pollution regulators could use WHO's discharge targets as a licence condition for bulk antibiotic makers. WHO wrote the 2024 guidance for regulators, buyers and inspectors, and allows a step-by-step rollout so that supply is not hurt [8].
- Public buyers of antibiotics, who are also among WHO's intended users, could favour suppliers that meet these targets [8].
12. Anchors for Answers
- Data: 'Watch'-group antibiotics made up 54.9% of India's antibiotic use (in DDDs) in 2019. Over half of the antibiotic formulations used that year were unapproved [4]
- Report/Committee: 59th Report of the Parliamentary Standing Committee on Health on the functioning of CDSCO, 2012 [6]. The 2013 Standing Committee report recommended centralised licensing of drug manufacture [7]
- Law/Case: NDCT Rules, 2019 ('New Drug' definition) and Drugs Rules, 1945 (bulk-drug sale licence), both under the Drugs and Cosmetics Act, 1940 [1]. The 2016 FDC ban was challenged in court by industry [5]
- Comparison: WHO's 2024 Guidance on wastewater and solid waste management for manufacturing of antibiotics sets discharge targets from API making to finished product, which India's licensing does not yet cover [8]
- Scheme: NAP-AMR 2.0 (released at WAAW 2025) is the policy framework this regulatory tightening serves [2]
13. Mains Relevance
- GS-II: Health; government policies and interventions; statutory and regulatory bodies.
- GS-III: Science & Technology (biotechnology, health); pharma industry; environment (pharma effluents).
- GS-IV (light): Ethics of profit versus public health in antibiotic marketing.
- Possible question stems: 1. Antimicrobial resistance is a silent pandemic. Evaluate India's regulatory response, including recent changes to drug-approval rules. (GS-II, 15M) 2. Discuss how the One Health approach under NAP-AMR 2.0 can address the multi-sectoral drivers of AMR in India. (GS-III, 10M) 3. Centralised scrutiny of drug approvals strengthens safety but strains cooperative federalism. Examine in the context of India's drug regulation. (GS-II, 15M)
14. Related Topics to Study Next
- NAP-AMR 2.0 (2025–29): the policy framework this regulation serves [2].
- Drugs and Cosmetics Act, 1940 and the proposed new Drugs, Medical Devices & Cosmetics Bill: the statutory base and its planned overhaul.
- CDSCO, DTAB and DCC: the bodies that recommend and implement these changes.
- Schedule H1 and the Red Line campaign: earlier curbs on antibiotic misuse.
- Fixed-dose combination (FDC) bans: closely related regulation of antibiotic combinations.
- PLI scheme for bulk drugs/APIs: links to the bulk-drug licensing reform.
- WHO Global Action Plan on AMR and the 2024 UNGA High-Level Meeting on AMR: the international framework.
- Kerala's KARSAP: the first state-level AMR action plan.
15. NCERT Concepts to Revise
- Antimicrobial resistance (Geography): AMR is the public-health threat driving the proposal to tighten licensing of antimicrobial products.
- New Drugs and Clinical Trials Rules, 2019 (Economy): These are the rules being amended so antimicrobials count as 'New Drug' needing central approval.
- Drugs Rules, 1945 (Polity): The second amendment creates a separate bulk-drug sale licence and form under these rules.
- Drugs and Cosmetics Act, 1940 (Polity): Parent law under which both sets of drug rules are made; base for understanding licensing.
- Central Drugs Standard Control Organisation (Polity): National drug regulator that would handle new-drug approvals for antimicrobials, with States licensing otherwise.
- National Action Plan on AMR (Economy): India's policy framework against AMR, which this regulatory tightening supports.
- One Health (Geography): Approach linking human, animal and environmental health that underpins NAP-AMR 2.0 and AMR control.
- Active pharmaceutical ingredient (Geography): Bulk drug means the active ingredient, the subject of the new separate sale licence.
- Fixed-Dose Combination (Polity): Related regulation: irrational antibiotic combinations are treated as new drugs and banned centrally.
- Cooperative federalism (Polity): Shifting antimicrobial approval from states to the Centre raises Centre–State regulatory coordination questions.
- Production-linked incentive (Economy): PLI scheme for bulk drugs links to API sector policy and supply-chain reform.
- Department of Pharmaceuticals (Polity): Trap: the Health Ministry proposes this, not the Department of Pharmaceuticals, which handles industry promotion.
16. Common Errors / Trap Areas
- Wrong rules: The 'New Drug' definition change is under the NDCT Rules, 2019. The bulk-drug licence change is under the Drugs Rules, 1945. Don't swap them [1].
- Wrong ministry: The Health Ministry is the proposer, not the Department of Pharmaceuticals (Ministry of Chemicals & Fertilizers) [1].
- Draft vs notified: In Nov 2026 these were proposed amendments, not final law [1].
- NAP-AMR versions: The first plan ran 2017–2021 [3]. Version 2.0 was released at WAAW 2025 [2].
- Bulk drug ≠ formulation: The reform creates separate licensing for the API, not the finished dosage form [1].
Sources
- 1Ministry seeks tighter norms for antimicrobials, bulk trade — The Hindu, 20 Nov 2026 (Page 6)thehindu.com · tier 4
- 2WAAW 2025: India's much awaited second version of the National Action Plan on AMR released — Down To Earthdowntoearth.org.in · tier 4
- 3National action plan on antimicrobial resistance (NAP-AMR) 2017–2021 — WHO India — )-2017---2021who.int · tier 2
- 4Over half the antibiotic formulations India used in 2019 were unapproved — Down To Earthdowntoearth.org.in · tier 4
- 5Indian government is not doing enough to tackle the sale of unapproved antibiotics — Down To Earthdowntoearth.org.in · tier 4
- 6Lapses in the process of drug approval in India — PRS Legislative Research blogprsindia.org · tier 1
- 7Standing Committee Report on drugs bill, 2013 — PRS Legislative Researchprsindia.org · tier 1
- 8Guidance on wastewater and solid waste management for manufacturing of antibiotics — WHOwho.int · tier 2